Evaluation of the Effectiveness and Tolerability of Mycophenolate Mofetil and Mycophenolic Acid for the Treatment of Morphea

Authors:

Abstract
Morphea (localized scleroderma) is a rare sclerosing disorder of the skin and subcutaneous tissue that affects patients of all ages.1-3 Patients with extensive involvement unresponsive to phototherapy, with facial involvement, or with involvement traversing joints require systemic treatment to prevent disease progression and its associated morbidity. Experts recommend treatment with methotrexate (MTX) for these patients.2-6 This recommendation is based on a randomized, double-blind, placebo-controlled clinical trial in a pediatric population comparing the combination of prednisone for 3 months and MTX for 12 months vs prednisone alone for 3 months.7 Those who received MTX demonstrated improved skin scores and were less likely to experience disease relapse compared with those who received placebo. In addition, several small retrospective studies and a prospective study have further supported the value and safety of MTX, with or without systemic corticosteroids (SCSs), for the treatment of morphea.8-15 For some patients, treatment with MTX is ineffective, not well tolerated, or contraindicated. Studies suggest that approximately 25% to 30% of patients with morphea will not show clinical improvement with MTX.7,12 In this subset of patients, a trial of mycophenolate mofetil (MMF) or mycophenolic acid (MPA)—referred to herein as mycophenolate—is recommended, although evidence supporting this practice is based on small case series.2,4,5

This publication has 23 references indexed in Scilit: